Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Novel mechanism of action - prevention of viral RNA exit from nucleus of infected cells - associated to unique anti-viral properties Unlike any...
ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in ...
ABX464's innovative mechanism of action could produce a long lasting reduction in the viral load in patients ABX464 could be administered less...
ABIVAX, a leading clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, is pleased to see the new...
ABIVAX, a leading clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced the...
ABIVAX, a leading European, clinical stage biopharmaceutical company developing and commercializing anti-viral compounds and human vaccines, today...
Karl Birthistle, M.D., appointed VP of Global Regulatory Affairs Daniel Kenny appointed Chief Commercial Officer & VP of Business Development ABIVAX, ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.